Loading...
Indian Pharmaceutical Exporter · Respiratory Specialist · $457.5K Total Trade · DGFT Verified
Noble Wellness Private Limited is an Indian pharmaceutical exporter with a total trade value of $457.5K across 2 products in 1 therapeutic categories. Based on 18 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Budesonide ($372.9K), Ipratropium ($84.6K), .
Noble Wellness Private Limited is an Indian pharmaceutical company established on April 24, 2012, in New Delhi, Delhi, India. The company is registered under the Corporate Identification Number (CIN) U24232DL2012PTC234745. It operates as a private limited company, classified as a non-government entity, and is unlisted on stock exchanges. The authorized capital stands at ₹0.50 million, with a paid-up capital of ₹0.10 million.
The registered office is located at Dtj810, 8th Floor, DLF Tower-B, DDA District Centre, Jasola, New Delhi, Delhi, 110025. The company specializes in the manufacturing and export of pharmaceutical formulations, including tablets, capsules, syrups, injections, and other dosage forms. Their product portfolio also encompasses herbal formulations, dietary supplements, and nutraceuticals.
Noble Wellness Private Limited operates across 1 therapeutic categories, with Respiratory (100.0%), representing the largest segments by export value. The portfolio is concentrated — the top 5 products account for 100% of total exports.
Respiratory
2 products · 100.0% · $457.5K
Noble Wellness Private Limited exports 2 pharmaceutical products across 1 therapeutic categories.
| # | Product | Category | Export Value | Shipments | Market Share | Rank |
|---|---|---|---|---|---|---|
| 1 | Budesonide | Respiratory | $372.9K | 10 | 0.2% |
Headquarters, ownership, manufacturing facilities, and key leadership
Noble Wellness Private Limited is an Indian pharmaceutical company established on April 24, 2012, in New Delhi, Delhi, India. The company is registered under the Corporate Identification Number (CIN) U24232DL2012PTC234745. It operates as a private limited company, classified as a non-government entity, and is unlisted on stock exchanges. The authorized capital stands at ₹0.50 million, with a paid-up capital of ₹0.10 million.
The registered office is located at Dtj810, 8th Floor, DLF Tower-B, DDA District Centre, Jasola, New Delhi, Delhi, 110025. The company specializes in the manufacturing and export of pharmaceutical formulations, including tablets, capsules, syrups, injections, and other dosage forms. Their product portfolio also encompasses herbal formulations, dietary supplements, and nutraceuticals.
Noble Wellness Private Limited operates manufacturing facilities in India, with the registered office situated in New Delhi. While specific details regarding the locations and capacities of their manufacturing plants are not publicly disclosed, the company emphasizes its commitment to quality and compliance with international standards. They hold certifications such as WHO-GMP and ISO, indicating adherence to stringent manufacturing practices.
| 12 |
| 2 | Ipratropium | Respiratory | $84.6K | 8 | 0.1% | 14 |
Noble Wellness Private Limited exports 2 pharmaceutical products across 1 therapeutic categories with a total export value of $457.5K. The top category is Respiratory (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.
Shipment-level records, pricing & buyer contacts for Noble Wellness Private Limited.
Request DemoThe leadership team at Noble Wellness Private Limited comprises:
The company does not publicly disclose the positions of Chief Executive Officer (CEO) or Chief Financial Officer (CFO). The directors are actively involved in the company's strategic direction and operations.
Regulated market presence, emerging market penetration, and geographic strategy
Noble Wellness Private Limited's export data indicates shipments to various international markets, including Mongolia, Afghanistan, and China. However, specific regulatory approvals or market access statuses in the United States, European Union, United Kingdom, Australia, and Japan are not publicly available. The company holds WHO-GMP and ISO certifications, which may facilitate entry into certain regulated markets.
The company's export activities in Mongolia, Afghanistan, and China suggest a presence in emerging markets. While specific details regarding WHO prequalification or other certifications enabling access to these markets are not disclosed, the company's adherence to international standards may support its expansion in these regions.
Noble Wellness Private Limited's export data indicates shipments to various international markets, including Mongolia, Afghanistan, and China. However, specific details regarding the company's geographic diversification strategy are not publicly available. The company's focus on international certifications such as WHO-GMP and ISO suggests a strategic direction towards meeting global quality standards.
FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record
Specific information regarding FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, or inspection history for Noble Wellness Private Limited is not publicly available. The company's export data indicates shipments to various international markets, including Mongolia, Afghanistan, and China. However, details regarding FDA approvals or market access are not disclosed.
Noble Wellness Private Limited holds WHO-GMP and ISO certifications, indicating compliance with international manufacturing standards. Specific details regarding EU GMP certificates or EDQM status are not publicly available.
The company is registered with the Ministry of Corporate Affairs under CIN U24232DL2012PTC234745. Specific details regarding CDSCO manufacturing licenses, state drug controller approvals, or export No Objection Certificates (NOCs) are not publicly disclosed.
There are no publicly available records of Form 483 observations, warning letters, or import alerts associated with Noble Wellness Private Limited. The company's adherence to international standards such as WHO-GMP and ISO certifications suggests a commitment to regulatory compliance.
Market share comparison, key differentiators, and strategic analysis
Noble Wellness Private Limited operates in the pharmaceutical manufacturing and export sector, competing with other Indian pharmaceutical companies in the same domain. Specific market share comparisons or head-to-head analyses are not publicly available. The company's focus on international certifications such as WHO-GMP and ISO may provide a competitive edge in global markets.
Noble Wellness Private Limited differentiates itself through its robust portfolio of both prescription and over-the-counter products, including tablets, capsules, syrups, injections, and more. The company also offers a wide range of herbal formulations, dietary supplements, and nutraceuticals. Additionally, their adherence to international standards, as evidenced by WHO-GMP and ISO certifications, underscores their commitment to quality and compliance.
Noble Wellness Private Limited's strategic direction appears to focus on manufacturing and exporting a diverse range of pharmaceutical formulations, including both prescription and over-the-counter products. The company's adherence to international standards such as WHO-GMP and ISO certifications suggests a commitment to quality and regulatory compliance. While specific details regarding future strategic plans are not publicly available, the company's existing certifications and product portfolio position it to cater to both generics and specialty markets.
Track record assessment, certifications to verify, and pre-order checks
Noble Wellness Private Limited's export data indicates shipments to various international markets, including Mongolia, Afghanistan, and China. The company's adherence to international standards, as evidenced by WHO-GMP and ISO certifications, suggests a reliable track record in manufacturing and exporting pharmaceutical products. However, specific details regarding export volume consistency and reliability indicators are not publicly available.
Importers should verify the following certifications to ensure product quality and regulatory compliance:
These certifications can typically be verified by requesting copies from the supplier or checking with the certifying bodies.
When considering a partnership with Noble Wellness Private Limited, importers should:
Red flags to watch for include expired certifications, lack of transparency in operations, or negative feedback from previous partners. Recommended pre-order checks involve requesting product samples, reviewing quality control processes, and conducting background checks on the company's financial stability.
Noble Wellness Private Limited exports 2 pharmaceutical products across 1 therapeutic categories. The top exports are Budesonide ($372.9K), Ipratropium ($84.6K). Total export value is $457.5K.
Noble Wellness Private Limited's total pharmaceutical export value is $457.5K, based on 18 verified shipments recorded in Indian Customs (DGFT) data.
Noble Wellness Private Limited exports across 1 therapeutic categories. The largest are Respiratory (100.0%, 2 products).
Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Verify manufacturer licensing, GMP certification, and export registration with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
2 Products Tracked
1 therapeutic categories
Expert-Reviewed
By pharmaceutical trade specialists
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.